泌尿器科領域に於ける17-Ketosteroidの研究補遺-3-
スポンサーリンク
概要
- 論文の詳細を見る
1) The amount of urinary 17-KS was clinically investigated on the patients with various urogenital diseases. 2) Administratio n of various hormones to the patients undergone bilatral orchiectomy, led the auther to the conclusion that estrogene therapy caused a decrease in urinary 17-KS excretion, while the other therapy caused an increase in the excretion. 3) The rate of 17-KS excretion after the transplantation of cow's endocrine organs, was generally apt to increase. 4) In the patients with prostatic hypertrophy and prostatic cancer, the average rate of urinary 17-KS excretion was within the normal range. The patients with prostatic cancer excreted much more amount of 17-KS into the urine that of prostatic hypertrophy. Most diseases of the bladder did not affect the rate of urinary 17-KS excretion except that of vesical cancer which decreased the rate of excretion more than vesical benign tumor. Hypernephroma especially, caused remarkably high level of the urinary excretion of 17-KS. 5) In most patients with renal tuberculosis, the rate of urinary 17-KS excretion were within or below the normal range. Unilateral or bilateral epididymectomy for tuberculosis generally produced no significance in the rate of urinary 17-KS excretion except for the aged patients whose rate of excretion was relatively low. 6) The rate of urinary 17-KS excretion in the ca s e of sexual dysfunction was within the normal range.
- 泌尿器科紀要刊行会の論文
泌尿器科紀要刊行会 | 論文
- MVAC療法後の転移性尿路上皮癌に対するGemcitabine, Docetaxel, Carboplatin併用化学療法の検討
- Grade 3 Ta-1表在性膀胱癌に対する膀胱温存治療
- 腹腔鏡下に摘出した後腹膜神経線維腫の1例
- 移植腎生検による腎内動脈瘤破裂の1例
- Modified M-VAC療法後に残存腫瘍切除を施行した進行尿路上皮癌患者の治療成績